AbbVie Inc.

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:03 06/02/2026 GMT			5-day change	1st Jan Change
223.43 ^USD	+2.01%		+1.36%	-2.21%

02-05	CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5)	RE
02-05	Evercore ISI Adjusts Price Target on AbbVie to $228 From $232, Maintains Outperform Rating	MT

Abbvie, US reach agreement to cut drug prices

Published on 01/12/2026 at 11:54 pm GMT - Modified on 01/13/2026 at 12:00 am GMT

Reuters

ABBVIE INC.

+2.01%

Abbvie, US reach agreement to cut drug prices

Jan 12 (Reuters) - Abbvie reached a three-year agreement with U.S. President Donald Trump's administration to provide low prices in Medicaid through TrumpRx, and pledged $100 billion over the next decade for research and development in the U.S., the company said on Monday.

(Reporting by Ruchika Khanna in Bengaluru; Editing by Chris Reese)

Latest news about AbbVie Inc.

02-05	CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5)	RE
02-05	Evercore ISI Adjusts Price Target on AbbVie to $228 From $232, Maintains Outperform Rating	MT
02-05	Goldman Sachs Adjusts Price Target on AbbVie to $240 From $223, Maintains Neutral Rating	MT
02-05	UBS Adjusts AbbVie Price Target to $230 From $240, Maintains Neutral Rating	MT
02-05	Morgan Stanley Lifts Price Target on AbbVie to $270 From $269, Keeps Overweight Rating	MT
02-04	Health Care Up After Eli Lilly Earnings -- Health Care Roundup	DJ
02-04	Nasdaq, S&P 500 Fall as Tech Sell-Off Continues	MT
02-04	Sector Update: Health Care Stocks Rise Late Afternoon	MT
02-04	Evercore ISI Adjusts AbbVie Price Target to $228 From $232, Maintains Outperform Rating	MT
02-04	Sector Update: Health Care Stocks Rise Wednesday Afternoon	MT
02-04	AbbVie Inc., Q4 2025 Earnings Call, Feb 04, 2026
02-04	AbbVie forecasts upbeat 2026 profit, but shares fall on key drug's sales miss	RE
02-04	Boston Scientific, AbbVie Beat Quarterly Views; Shares Slump Amid Weakness in Certain Segments	MT
02-04	AbbVie Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-04	AbbVie Q4 Adjusted Earnings, Revenue Rise; 2026 Adjusted Earnings Guidance Issued	MT
02-04	AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs	RE
02-04	Wall Street: When AI Stops Being a Buzzword and Starts Being a Threat
02-04	Agilent Technologies Inc. Showcases Next-Generation Automated Solutions at SLAS2026	CI
02-04	AbbVie Q4 Adjusted Earnings, Revenue Rise; 2026 Adjusted Earnings Guidance Issued	MT
02-04	AbbVie 4Q Revenue Rises on Immunology Growth	DJ
02-04	(ABBV) AbbVie Expects 2026 Adjusted EPS Range $14.37 to $14.57, vs. FactSet Est of $14.27	MT
02-04	Earnings Flash (ABBV) AbbVie Posts Q4 Net Revenue $16.62B, vs. FactSet Est of $16.41B	MT
02-04	Earnings Flash (ABBV) AbbVie Posts Q4 Adjusted EPS $2.71, vs. FactSet Est of $2.65	MT
02-04	AbbVie forecasts upbeat 2026 profit, but shares fall on key drug's sales miss	RE
02-04	Stocks Rise Pre-Bell Following End of Partial Government Shutdown; Alphabet Earnings on Deck	MT

Chart AbbVie Inc.

Duration

Period

ABBV: Dynamic Chart

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.4%), Germany (2.6%), Japan (2%), Canada (1.9%), China (1.6%), France (1.4%), Spain (1%), the United Kingdom (0.9%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and other (9.7%).

Employees

55,000

Sector

Pharmaceuticals

Calendar

04-23 - Q1 2026 Earnings Release (Projected)

More about the company